Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary

Adjuvant chemotherapy improves disease-free survival (DFS) and overall survival (OS) independent of age, nodal status, and estrogen receptor (ER) status. However, those with triple-negative and human epidermal growth factor receptor 2 (HER2) –positive breast cancer seem to derive the greatest proportional benefit from systemic chemotherapy and biologic therapy. The potential benefits and risks need to be carefully weighed before a decision to administer chemotherapy is rendered; comorbidities and burden of disease need to be considered for selection of optimal regimens.

 Journal of Oncology Practice